等待开盘 11-18 09:30:00 美东时间
-0.260
-4.02%
Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 35.9 percent decrease over losses of $(0.39) per share from the same period last year.
11-12 20:20
Satellos Bioscience Inc. will host a conference call and audio webcast on Nov. 6, 2026, at 8:00 a.m. ET to discuss updates on the clinical and regulatory strategy for its Phase 2 pediatric study, BASECAMP, for Duchenne muscular dystrophy (DMD). The call will feature remarks from Satellos' CEO Frank Gleeson and Chief Medical Officer Wildon Farwell, M.D. A live webcast with accompanying slides will be available on the company's website, with a repl...
11-05 21:32
Satellos Bioscience ( ($TSE:MSCL) ) has issued an announcement. Satellos Biosci...
10-21 19:27
Satellos Bioscience Inc. announced its participation in two upcoming investor conferences in November 2026: the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 9 and the Jefferies Global Healthcare Conference in London on November 18-19. The company will also host one-on-one investor meetings at both events. Satellos, focused on developing treatments for degenerative muscle diseases, is advancing forazapadin, an AAK1 ...
10-21 11:00
今日重点评级关注:奥本海默:维持Aurora Innovation"跑赢大市"评级,目标价从15美元升至16美元;富国银行:维持Applied Digital"超配"评级,目标价从50美元升至55美元
10-09 16:25
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,747,245, entitled "AP2 a...
10-05 19:10
Satellos Bioscience Inc. has been granted U.S. Patent No. 12,747,245, providing composition of matter protection for forazapadin, its lead drug candidate, through Sept. 6, 2044. The patent covers forazapadin and a broader class of AAK1 inhibitors, supporting Satellos' long-term development and commercialization strategy. Forazapadin, an oral, small molecule drug, targets AAK1 to help restore muscle repair and regeneration, addressing degenerative...
10-05 11:00
FDA clearance expands development of forazapadin into a second degenerative muscle disease with significant unmet medical need FSHD Canada Foundation to provide up to US$5 million in non-dilutive financing toward the clinical development of forazapadin in FSHD Phase 2 study in FSHD expected to begin...
09-24 19:01
Satellos Bioscience announced FDA clearance for its IND application to develop forazapadin for facioscapulohumeral muscular dystrophy (FSHD). The company plans to initiate a Phase 2 clinical trial in Q4 2026. FSHD Canada Foundation will provide up to $5 million in non-dilutive financing. FSHD affects ~800,000 globally, with no approved therapies. Forazapadin is also being studied for Duchenne muscular dystrophy, showing promising early results.
09-24 11:00
Satellos Bioscience Inc. announced four poster presentations at the 31st Annual Congress of the World Muscle Society (WMS) in Hiroshima, Japan. The posters highlight clinical and preclinical studies of Forazapadin (SAT-3247), a novel AAK1 inhibitor targeting Duchenne muscular dystrophy (DMD) and other degenerative muscle diseases. Presentations include Phase 2a and long-term safety studies in DMD patients, preclinical to human translation of musc...
09-15 11:00